INTERPACE BIOSCIENCES, INC. 8-K

What Happened

• On January 20, 2026, Interpace Biosciences, Inc. (NASDAQ: IDXG) issued a press release announcing preliminary, unaudited revenue for the year ended December 31, 2025 and that all outstanding shares of its Series C Preferred Stock were converted into shares of common stock. The press release is furnished as Exhibit 99.1 to the Form 8‑K.
• The Form 8‑K notes the information in Items 2.02 and 7.01 (including Exhibit 99.1) is being furnished, not filed, and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings.

Key Details

• Filing date: January 20, 2026; reporting preliminary and unaudited revenue for the year ended December 31, 2025.
• Capital structure change: all outstanding Series C Preferred Stock converted into common stock (no conversion amounts reported in the 8‑K; see Exhibit 99.1 for details).
• Disclosure treatment: the press release and related statements are furnished (Exhibit 99.1) and not “filed” for Section 18 purposes.

Why It Matters

• Investors get an early, preliminary view of Interpace’s 2025 revenue performance ahead of audited financial statements and formal filings; figures in the press release should be confirmed when the company releases audited results.
• The conversion of Series C preferred shares removes that preferred tranche from the company’s capital structure and could affect the company’s common share count and dilution; investors should watch for subsequent filings or disclosures that quantify the conversion and updated outstanding share totals.